STEP I: Patient enrolling to this study must agree to register to the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssistXx_NEWLINE_xXSTEP II: Patient enrolling to this study must agree to register to the mandatory RevAssist program and be willing and able to comply with the requirements of RevAssistXx_NEWLINE_xXAll study participants must be registered into the mandatory POMALYST REMS program and be willing and able to comply with the requirements of the POMALYST REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the POMALYST REMS programXx_NEWLINE_xXAble to understand and voluntarily sign the ICF and able to comply with the study visit schedule and the other protocol requirements.Xx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants in the United States (US) must be consented to and registered into the mandatory revlimid (lenalidomide) REMS program and be willing and able to comply with the requirements of revlimid REMSXx_NEWLINE_xXMust be able to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXFCPB must have a negative urine or serum pregnancy test within 7 days prior to registration, and be willing to adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategies (REMS®) program\r\n* NOTE: should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediatelyXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® programXx_NEWLINE_xXSubjects must agree to adhere to all study requirements, visit schedule, outpatient treatment, required concomitant medications, and laboratory monitoringXx_NEWLINE_xXAll study participants must be registered into the mandatory POMALYST (pomalidomide) Risk Evaluation and Mitigation Strategy (REMS)(TM) program, and be willing and able to comply with the requirements of the POMALYST REMS(TM) program; for subjects enrolled outside of the United States, Pomalidomide counseling but be completed by a designated counselorXx_NEWLINE_xXFemales of reproductive potential must be willing to adhere to the scheduled pregnancy testing as required in the REVLIMID Risk Evaluation and Mitigation Strategy (REMS) programXx_NEWLINE_xXWilling to be registered into the mandatory REVLIMID REMS program, and willing and able to comply with the requirements of the REVLIMID REMS programXx_NEWLINE_xXSubject is willing and able to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAgree to adhere to all study protocol requirements.Xx_NEWLINE_xXWilling to adhere to protocol prohibitions and restrictionsXx_NEWLINE_xXAble to comply with the study visit schedule and other protocol requirements.Xx_NEWLINE_xXPatient willing to conform to the study requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXWilling and able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXThe patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.Xx_NEWLINE_xXMust be able to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXAll study participants must be registered into the mandatory pomalidomide (POMALYST) Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the POMALYST REMS programXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid (lenalidomide) Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXIs willing and able to adhere to the study visit schedule and other protocol requirements including blood sampling and bone marrow aspiration.Xx_NEWLINE_xXAble to adhere to study schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered in the Revlimid (lenalidomide) Risk Evaluation and Mitigation Strategy (RevREMS) program and be willing and able to comply with the requirements of REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of REMSXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirements in the opinion of the investigator.Xx_NEWLINE_xXSubjects must be willing to give written informed consent per institutional guidelines and must be able and willing to adhere to dose and visit schedulesXx_NEWLINE_xXBe willing/able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXAble to provide informed consent, adhere to the study schedule, and complete all study assessments.Xx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS program and be willing to comply with its requirements; per standard Revlimid REMS program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS programXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXSubjects must be willing to adhere to the dietary modification outlined in the protocol.Xx_NEWLINE_xXBe willing/able to adhere to the prohibitions and restrictions specified in this protocol.Xx_NEWLINE_xXAbility to adhere to the protocol requirements and study visit schedule.Xx_NEWLINE_xXSubject (and when applicable, with parental/legal representative) is willing and able to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXAll subjects must agree to comply with and be enrolled in Revlimid Risk Evaluation and Mitigation Strategy (REMS) programXx_NEWLINE_xXPatient must be willing to give written informed consent and must be able to adhere to dosing and visit schedules, and meet all study requirements.Xx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of Revlimid REMS; NOTE: females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMSTM programXx_NEWLINE_xXWilling to follow the requirements of the Pomalyst REMS programXx_NEWLINE_xXAbility to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory pomalidomide (POMALYST) Risk Evaluation and Mitigation Strategy (REMS) program and be willing and able to comply with the requirements of the POMALYST REMS programXx_NEWLINE_xXFemales of reproductive potential must agree to adhere to the scheduled pregnancy testing as required in the POMALYST REMS programXx_NEWLINE_xXPatient, or patient's authorized representative, must be willing and capable of giving written Informed Consent and must be able to adhere to dosing and visit schedules as well as meet all study requirementsXx_NEWLINE_xXAgree to be registered in and comply with all requirements of the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program (Cohorts B, C, E)Xx_NEWLINE_xXAgree to be registered in and comply with all requirements of the Pomalyst REMS program (Cohort F)Xx_NEWLINE_xXPersons able to become pregnant must be willing to adhere to the scheduled pregnancy testing as required in the REVLIMID Risk Evaluation and Mitigation Strategy (REMS) programXx_NEWLINE_xXWilling to be registered into the mandatory REVLIMID REMS program, and willing and able to comply with the requirements of the REVLIMID REMS programXx_NEWLINE_xXWilling to follow the requirements of the Revlimid Risk Evaluation and Mitigation Strategy (REMS) programXx_NEWLINE_xXAbility to provide informed written consent and be able to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXRegistered into Revlimid Risk Evaluation and Mitigation Strategy (REMS) programXx_NEWLINE_xXAbility to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid risk evaluation and mitigation strategy (REMS) program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXAll study participants in the US must be consented to and registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program and be willing and able to comply with the requirements of Revlimid REMSXx_NEWLINE_xXWilling to adhere to the guidelines of the Revlimid REMS (formerly known as RevAssist) program\r\n* NOTE: The counseling must be documentedXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must agree to be registered into the mandatory REVLIMID REMS program, and be willing and able to comply with the requirements of the REVLIMID REMS programXx_NEWLINE_xXAll study participants must be willing to register with the mandatory RevAssist program and be willing to comply with its requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXPatient must be able to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXBe willing/able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXWilling to adhere to the prohibitions and restrictions specified in this protocol (Notation: the subject's willingness to adhere to prohibitions and restrictions must be clearly communicated in the on-study note)Xx_NEWLINE_xXBe willing/able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXSubjects must be willing to give written informed consent per institutional guidelines and must be able and willing to adhere to dose and visit schedulesXx_NEWLINE_xXAbility to provide informed written consent and be able to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXPatient is willing to participate to the study, has the ability to adhere to the study visit schedule and other protocol procedures, and has the ability to understand and signs an informed consent formXx_NEWLINE_xXAll study participants must agree to be registered into the mandatory POMALYST Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the POMALYST REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the POMALYST REMS programXx_NEWLINE_xXWilling to comply with proposed visit and treatment scheduleXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXWilling and able to register into and comply with the mandatory requirements of Celgene’s REVLIMID REMS programXx_NEWLINE_xXFemales of reproductive potential are willing and able to adhere to the scheduled pregnancy testing as required by Celgene’s REVLIMID REMS programXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS program and be willing to comply with its requirements; per standard Revlimid REMS program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS programXx_NEWLINE_xXNegative serum or urine pregnancy tests during screening and then within 3 days prior to Day 1. 12. Sexually active men - effective contraceptive methods in subject and partner from the time of informed consent and until ? 4 weeks after discontinuing study drugs. 13. Able to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS), and be willing and able to comply with the requirements of the Revlimid REMSXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the Revlimid REMSXx_NEWLINE_xXWilling to adhere to and comply with all prohibitions and restrictions specified in the protocolXx_NEWLINE_xXAll study participants be willing and able to comply with the requirements of the Risk Evaluation and Mitigation Strategies (REMS) programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXPatient enrolling to this study must agree to register to the mandatory REVLIMID Risk Evaluation and Mitigation Strategy (REMS [TM]) program, and be willing and able to comply with the requirements of (REVLIMID REMS [TM])Xx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of Revlimid REMS programXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be willing to be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program after completion of induction chemoimmunotherapy and prior to maintenance therapy, and be willing and able to comply with the requirements of the Revlimid REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXAll study participants must be registered into the mandatory POMALYST REMS™ program, and be willing and able to comply with the requirements of the POMALYST REMS™ programXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the Revlimid REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXAll study participants must agree to be registered into the mandatory POMALYST REMS program, and be willing and able to comply with the requirements of the POMALYST REMS programXx_NEWLINE_xXFemales of reproductive potential must be willing to adhere to the scheduled pregnancy testing as required in the POMALYST REMS programXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of Revlimid REMSXx_NEWLINE_xXWilling/able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssistXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXWillingness to follow the requirements of the intravenous ascorbic acid program scheduleXx_NEWLINE_xXParticipant must be able to adhere to study visit/procedure schedule and protocol requirementsXx_NEWLINE_xXParticipant unwilling to adhere to study visit/procedure schedule and protocol requirementsXx_NEWLINE_xXSubject is registered into the mandatory RevAssist® program, and is willing and able to comply with the requirements of RevAssist® program.Xx_NEWLINE_xXAbility to adhere with the study visit schedule and other protocol proceduresXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the Revlimid REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXMust be able and willing to adhere to protocol requirements, visits and vaccination timelineXx_NEWLINE_xXAbility to voluntarily sign consent for and adhere to the entire study visit schedule and all protocol requirementsXx_NEWLINE_xXBe willing and able to comply with the protocol-required visit schedule and visit requirements and provide written informed consentXx_NEWLINE_xXAble to adhere to study visit schedule and other protocol requirements.Xx_NEWLINE_xXAble to adhere to study visit schedule and other protocol requirementsXx_NEWLINE_xXORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Willing and able to give informed consent and adhere to protocol therapyXx_NEWLINE_xXHPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Willing and able to give informed consent and adhere to protocol therapyXx_NEWLINE_xXRegistered into mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) programXx_NEWLINE_xXWomen of childbearing potential: adhere to scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXAbility to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategies (REMS) programXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXLactating or pregnant patients or patients of reproductive potential not willing to use effective methods of contraception and adhere to the Revlimid REMS programXx_NEWLINE_xXAll patients must be registered in and must comply with all requirements of the Revlimid Rems program.Xx_NEWLINE_xXAll study participants must be registered into the mandatory pomalidomide (POMALYST) REMS program, and be willing and able to comply with the requirements of the POMALYST REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the POMALYST REMS programXx_NEWLINE_xXAll study participants must be registered into the mandatory POMALYST (pomalidomide) Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the POMALYST REMS programXx_NEWLINE_xXWilling and able to comply with the requirements of the Revlimid Risk Evaluation and Mitigation Strategy (REMS) programXx_NEWLINE_xXFemales of childbearing potential must be willing to adhere to the scheduled pregnancy testing as required by the Revlimid REMS programXx_NEWLINE_xXWilling to adhere to the prohibitions and restrictions specified in the protocolXx_NEWLINE_xXWilling to adhere to the prohibitions and restrictions specified in the protocol.Xx_NEWLINE_xXFemales of reproductive potential must be willing to adhere to the scheduled pregnancy testing as required in the POMALYST REMS (TM) programXx_NEWLINE_xXWilling to be registered into the mandatory POMALYST REMS (TM) program, and willing and able to comply with the requirements of the POMALYST REMS (TM) programXx_NEWLINE_xXIf assigned to receive lenalidomide and a female of reproductive potential, must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS) programXx_NEWLINE_xXIf assigned to receive lenalidomide, patient must be registered into the mandatory Revlimid REMS program and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXBe able and willing to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXSubjects must be willing to give written informed consent per institutional guidelines and must be able to adhere to dose and visit schedulesXx_NEWLINE_xXWilling to adhere to the study visit schedule and prohibitions and restrictions specified in this study protocolXx_NEWLINE_xXWilling to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of Revlimid REMSXx_NEWLINE_xXSubject is willing and able to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirements Disease Specific 4. Histologically or cytologically confirmed Stage IIIB or IV squamous cell Non Small Cell Lung Cancer at study entry.Xx_NEWLINE_xXSubject is able to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXThe patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment. Inclusion Criteria:Xx_NEWLINE_xXThe patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.Xx_NEWLINE_xXMust also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, ORXx_NEWLINE_xXMust also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, ORXx_NEWLINE_xXSubject is willing and able to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXWilling and able to adhere to the study visit schedule and other protocol requirements. MDS Cohort:Xx_NEWLINE_xXBe willing/able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXWilling and able to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program and be willing to comply with its requirements; per standard Revlimid REMS program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS programXx_NEWLINE_xXAbility to adhere to the study visit schedule and all protocol requirements;Xx_NEWLINE_xXWilling to adhere to the prohibitions and restrictions specified in this protocol.Xx_NEWLINE_xXPatients must be registered to the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS)™ program and must be willing and able to comply with the requirements of the Revlimid REMS™ programXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid (lenalidomide) Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of Revlimid REMSXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS ™ Revlimid REMS™ program, and be willing and able to comply with the requirements of Revlimid REMS™Xx_NEWLINE_xXWilling to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS program, and be\r\nwilling and able to comply with the requirements of the REMS programXx_NEWLINE_xXWilling to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXWilling and able to give informed consent and adhere to protocol therapyXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS)TM program, and be willing and able to comply with the requirements of the Revlimid REMSTM program; females of childbearing potential must adhere to the scheduled pregnancy testing and contraception as required in the Revlimid REMSTM program; a female of childbearing potential (FCBP) is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)Xx_NEWLINE_xXWillingness to follow study visit schedule, pregnancy precautions and other protocol requirements.Xx_NEWLINE_xXPatient agrees that if randomized to Arms C or D, and proceeding onto Arms G or H, they must register into the mandatory Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of RemsXx_NEWLINE_xXAll study participants must be registered into the mandatory Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of REMSXx_NEWLINE_xXThe patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.Xx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXPatient is able and willing to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXPatient must be willing to give written informed consent and must be able to adhere to dosing and visit schedules, and meet all study requirements.Xx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXPatient must be able to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXParticipant is willing to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXMust be able to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXFemales of reproductive potential who will receive lenalidomide must adhere to the scheduled pregnancy testing as required in the Revlimid REMS(TM) programXx_NEWLINE_xXAll study participants who will receive lenalidomide must be registered into the mandatory Revlimid REMS(TM) program, and be willing and able to comply with the requirements of the REMS(TM) programXx_NEWLINE_xXAll study participants enrolled in the lenalidomide containing cohort (cohort 2) must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXSubject must be able to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid (lenalidomide) Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXMust also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, ORXx_NEWLINE_xXMust also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, ORXx_NEWLINE_xXIs willing and able to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXAll study participants must be registered into the mandatory POMALYST REMS program, and be willing and able to comply with the requirements of the POMALYST REMS programXx_NEWLINE_xXAbility to provide informed written consent and be able to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll patients enrolled into this trial, must be registered in and must comply with all requirements of the POMALYST (pomalidomide) Risk Evaluation and Mitigation Strategy (REMS) programXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXMust be registered into the mandatory RevAssist® program and be willing and able to comply with the requirement of RevAssist®Xx_NEWLINE_xXBe willing/able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAbility to voluntarily sign consent for and adhere to the entire study visit schedule and all protocol requirementsXx_NEWLINE_xXBe willing/able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS program and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXAll study participants must be registered into the mandatory electronic Risk Evaluation and Mitigation Strategies (eREMS) program, and be willing and able to comply with the requirements of REMSXx_NEWLINE_xXAll study participants must be registered into the mandatory POMALYST (pomalidomide) Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the POMALYST REMS programXx_NEWLINE_xXBe willing/able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXWilling/able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXAble to adhere to the study visit schedule (ie, clinic visits at the study sites are mandatory, unless noted otherwise for particular study visits) and other protocol requirements.Xx_NEWLINE_xXPatient is willing and able to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAbility to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants enrolled in the United States must be registered into the mandatory REVLIMID Rems program and be willing and able to comply with the requirements of REVLIMID RemsXx_NEWLINE_xXSubjects must agree to adhere to all study requirements, including birth control measures and pregnancy testing, visit schedule, outpatient treatment, required concomitant medications, and laboratory monitoringXx_NEWLINE_xXBe willing/able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXMust be able to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXAll study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssistXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory POMALYST Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the POMALYST REMS programXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory POMALYST REMS program, and be willing and able to comply with the requirements of the POMALYST REMS programXx_NEWLINE_xXAble to adhere to study schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssistXx_NEWLINE_xXWilling and able to adhere to the protocol requirements, including but not limited to study drug dosing, study drug visits, medication and treatment restrictions, and laboratory testsXx_NEWLINE_xXSubjects must agree to follow all Guidelines from REVLIMID REMS Program or POMALYST REMSXx_NEWLINE_xXPatients must be willing and able to sign the informed consent form, and to follow the study visit schedule and other protocol requirements.Xx_NEWLINE_xXWas willing and able to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of Revlimid REMS programXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of REMSXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXAll subjects must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.Xx_NEWLINE_xXWilling to adhere to and comply with all prohibitions and restrictions specified in the protocolXx_NEWLINE_xXAll study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssistXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®. All counseling will be done through RevAssist®.Xx_NEWLINE_xXSubjects must be willing to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXPatient must be able to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXPatient must be registered into the mandatory Revlimid REMS program and be willing and able to comply with the requirements of Revlimid REMSXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssistXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssistXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssistXx_NEWLINE_xXPatient must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.Xx_NEWLINE_xXAll study participants must be registered into the mandatory electronic Risk Evaluation and Mitigation Strategies (eREMS) program, and be willing and able to comply with the requirements of REMSXx_NEWLINE_xXAbility to adhere to dose and visit schedules.Xx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of Revlimid REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXMust be able to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the Revlimid REMS programXx_NEWLINE_xXMust be able to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXSubject is able to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid risk evaluation and mitigation strategy (REMS) program, and be willing and able to comply with the requirements of Revlimid REMSXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXAbility to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid assistance (RevAssist) program, and be willing and able to comply with the requirements of RevAssistXx_NEWLINE_xXAll study participants must be registered into the mandatory RevAssist program and be willing and able to comply with the requirements of RevAssistXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXFemales of childbearing potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXInability to co-operate with the study visit schedule and other requirements of the protocolXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXBe willing/able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXAll study participants must be willing to be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS)® program, and be willing and able to comply with the requirements of the REMS® program; NOTE: Actual registration in the Revlimid REMS® program may occur after the patient is randomized since this requirement only applies to patients randomized to Arm AXx_NEWLINE_xXFemales of reproductive potential must be willing to adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program; NOTE: This requirement only applies to patients randomized to Arm AXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS)® program, and be willing and able to comply with the requirements of Revlimid REMS®Xx_NEWLINE_xXBe willing/able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXWilling and able to comply with post-operative treatment protocol and follow-up visit schedule.Xx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirements. Disease SpecificXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAble to comply with study visit schedule and assessments.Xx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of Revlimid REMS®; drug dispensing must come from the Celgene approved pharmacy, Biologics (Clinical Trials Services)Xx_NEWLINE_xXPatients must be informed of the Celgene Risk Management Program and mandatory registration as well as be willing and able to comply with its requirementsXx_NEWLINE_xXPatients must be willing and able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of Revlimid REMS®Xx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXIn order to obtain lenalidomide, patients must be registered into the mandatory RevlimidREMS program during the maintenance phase of therapy, and be willing and able to comply with the requirements of RevlimidREMSXx_NEWLINE_xXThe patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.Xx_NEWLINE_xXAll study participants must be registered into the mandatory lenalidomide Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the lenalidomide REMS programXx_NEWLINE_xXBe willing/able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXAll study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssistXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssistXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS®) program, and be willing and able to comply with the requirements of the REMS® programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® programXx_NEWLINE_xXAble to adhere to study visit schedule and other protocol requirementsXx_NEWLINE_xXSubjects must be willing to give written informed consent and be able to adhere to dose and visit schedules.Xx_NEWLINE_xXAble to adhere to the study visit schedule and requirements of the protocolXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXPatients must be willing and able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS)® programXx_NEWLINE_xXWilling to be registered into the mandatory Revlimid REMS® program, and willing and able to comply with the requirements of the REMS® programXx_NEWLINE_xXWilling and able to meet all study requirementsXx_NEWLINE_xXSubjects must be willing to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAble to adhere to study schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of the REMs program; females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXBe willing/able to adhere to the prohibitions and restrictions specified in this protocolXx_NEWLINE_xXBe willing and able to adhere to all study-related proceduresXx_NEWLINE_xXWilling and able to do all study requirementsXx_NEWLINE_xXWilling and able to meet all study requirementsXx_NEWLINE_xXPatients must be willing to adhere to the PNP intervention and the entire 6-month studyXx_NEWLINE_xXAre willing and able to complete study requirementsXx_NEWLINE_xXWilling and able to meet all study requirementsXx_NEWLINE_xXWilling and able to meet all study requirementsXx_NEWLINE_xXAble to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS programXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS programXx_NEWLINE_xXWillingness to adhere to the study visit schedule and prohibitions as specified in this protocolXx_NEWLINE_xXAll study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® programXx_NEWLINE_xXWilling and able to schedule mastectomy 4 weeks (+/- 7days) following start of study agentXx_NEWLINE_xXWilling to give written informed consent, adhere to the visit schedules and meet study requirementsXx_NEWLINE_xXBe able to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXSubject is willing and able to adhere to the study visit schedule and other protocol requirements.Xx_NEWLINE_xXWilling and able to provide informed consent and adhere to the study visit schedule and plan as specified in this protocolXx_NEWLINE_xXPatients who are not planning to adhere to the required follow up schedule as outlined in this protocolXx_NEWLINE_xXAble to understand study requirementsXx_NEWLINE_xXWilling and able to give informed consent and adhere to visit/protocol schedulesXx_NEWLINE_xXWilling and able to follow the protocol requirements.Xx_NEWLINE_xXAble to adhere to study visit schedule and other protocol requirements including follow-up for survival assessmentXx_NEWLINE_xXPatients who are not planning to adhere to the required follow up schedule as outlined in this protocolXx_NEWLINE_xXWilling and able to adhere to the study visit schedule and other protocol requirementsXx_NEWLINE_xX